The catastrophic antiphospholipid syndrome

Antiphospholipid Antibody Syndrome: From Bench to Bedside

Volumn , Issue , 2015, Pages 249-262

  Rodríguez Pintó, Ignasi ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Asherson s syndrome; Catastrophic APS; Cytokine storm; Microangiphatic storm; Thrombotic storm

Indexed keywords

EID: 84944537139     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-11044-8_20     Document Type: Chapter

References (62)

1. Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508-512
2. Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019-1027
3. Cervera R, Rodríguez-Pintó I, Espinosa G (2014) On behalf of the Task Force on Catastrophic Antiphospholipid Syndrome. Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283-1285
4. Cervera R (2012) CAPS registry. Lupus 21:755-757
5. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G et al (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 32:240-245
6. Ortega-Hernandez O-D, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y (2009) The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 32:1-6
7. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A et al (2000) Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 15:237-240
8. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A et al (2003) Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101:3495-3500
9. Asherson RA, Shoenfeld Y (2000) The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome-molecular mimicry? J Rheumatol 27:12-14
10. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS (2005) Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 52:1545-1554
11. Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A et al (2011) In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 118:4231-4238
12. Shoenfeld Y, Meroni PL, Toubi E (2009) Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? Curr Opin Rheumatol 21:495-500
13. Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CEM et al (2014) Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "caps registry.". Autoimmun Rev 13:157-162
14. Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216
15. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398-401
16. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR (2012) A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 119:884-893
17. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689-10692
18. Xie H, Sheng L, Zhou H, Yan J (2014) The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. Br J Haematol 164:165-176
19. Levi M, Schultz M, van der Poll T (2013) Sepsis and thrombosis. Semin Thromb Hemost 39:559-566
20. Levi M (2008) The coagulant response in sepsis. Clin Chest Med 29:627-642, viii
21. Kitchens CS (1998) Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104: 381-385
22. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C et al (2014) 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 13:699-707
23. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S et al (2006) The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev 6:94-97
24. Cervera R, Asherson RA, Acevedo ML, Gómez-Puerta JA, Espinosa G, De La Red G et al (2004) Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63:1312-1317
25. Trousseau A (1865) Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris, pp 281-332
26. Anderson FA, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107:I9-I16
27. Reed RL, Ericsson CD, Wu A, Miller-Crotchett P, Fischer RP (1992) The pharmacokinetics of prophylactic antibiotics in trauma. J Trauma 32:21-27
28. Rodríguez-pintó I, Espinosa G, Cervera R (2013) Catastrophic antiphospholipid syndrome - 20 years later. Curr Rheumatol Rev 9:73-80
29. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A et al (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195-207
30. Cervera R, Espinosa G (2012) Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Semin Thromb Hemost 38:333-338
31. Gruel Y, Rupin A, Watier H, Vigier S, Bardos P, Leroy J (1992) Anticardiolipin antibodies in heparin-associated thrombocytopenia. Thromb Res 67:601-606
32. Levi M, Keller TT, van Gorp E, ten Cate H (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60:26-39
33. Spero JA, Lewis JH, Hasiba U (1980) Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 43:28-33
34. Siegal T, Seligsohn U, Aghai E, Modan M (1978) Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 39:122-134
35. Taylor FB Jr, Toh C, Hoots WK, Wada H, Levi M, Scientific and Standardization Committee Communications, On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327-1330
36. Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S et al (2005) Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 64:943-946
37. George JN, Charania RS (2013) Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 39:153-160
38. Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809-817
39. Cervera R (2010) Catastrophic antiphospholipid syndrome (CAPS): update from the "CAPS Registry". Lupus 19:412-418
40. Amital H, Levy Y, Davidson C, Lundberg I, Harju A, Kosach Y et al (2001) Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin Arthritis Rheum 31:127-132
41. Sacks S, Finn J, Sanna G, Khamashta MA, Chowdhury F, Hunt BJ et al (2013) N2010 adultonset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation. Isr Med Assoc J 15:192-194
42. Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC (2002) Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 8:157-165
43. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D et al (2011) Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 20:174-181
44. Erkan D (2006) Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6:98-103
45. Weitz JI, Hirsh J, Samama MM (2004) New anticoagulant drugs: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126:265S-286S
46. Franklin RD, Kutteh WH (2003) Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 101:455-462
47. Manoach S (2008) Corticosteroids for septic shock. N Engl J Med 358:2070; author reply 2070-2071
48. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M et al (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:2268-2576
49. Sciascia S, Giachino O, Roccatello D (2012) Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 30:409-413
50. Tenti S, Guidelli GM, Bellisai F, Galeazzi M, Fioravanti A (2013) Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin Exp Rheumatol 31:877-882
51. Bucciarelli S, Erkan D, Espinosa G, Cervera R (2009) Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 36:80-84
52. Erkan D, Espinosa G, Cervera R (2010) Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 10:74-79
53. Asherson R, Cervera R, de Groot PG, Erkan D, Boffa M-CC, Piette J-CC et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-534
54. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588-596
55. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909-920
56. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767-776
57. Calich AL, Puéchal X, Pugnet G, London J, Terrier B, Charles P et al (2014) Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 50:135-141
58. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A, Puéchal X et al (2014) Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 160:233-242
59. Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D et al (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12:1085-1090
60. Espinosa G, Bucciarelli S, Asherson RA, Cervera R (2008) Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 34:290-294
61. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette J-C et al (2003) Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 62:530-533
62. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R (2012) Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum 42:417-423